Correlation analysis of serum cystatin C, uric acid and lactate dehydrogenase levels before chemotherapy on the prognosis of small‑cell lung cancer

Wang,Haocheng; Shan,Dongfeng; Dong,Ya; Yang,Xue; Zhang,Linwei; Yu,Zhuang

doi:10.3892/ol.2020.12334

Correlation analysis of serum cystatin C, uric acid and lactate dehydrogenase levels before chemotherapy on the prognosis of small‑cell lung cancer

Authors:
- Haocheng Wang
- Dongfeng Shan
- Ya Dong
- Xue Yang
- Linwei Zhang
- Zhuang Yu
View Affiliations

Affiliations: Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China
Published online on: November 25, 2020 https://doi.org/10.3892/ol.2020.12334
Article Number: 73
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Related studies have reported that cystatin C (Cys C), uric acid (UA) and lactate dehydrogenase (LDH) affect tumor growth and invasion; however, the correlation between them and the prognosis of patients with small‑cell lung cancer (SCLC) remains unclear. The present study aimed to investigate the effects of serum Cys C, UA and LDH concentrations on the prognosis of patients with SCLC prior to initial treatment, in order to identify potential targets for determining the clinical outcome of patients with SCLC. A total of 205 patients with SCLC were enrolled in the present study, and the clinical and laboratory data were obtained from the medical records. The receiver operating characteristic curve was used to determine the optimal cut‑off values of Cys C, UA and LDH, while the Kaplan‑Meier method was used for survival analysis. The Cox proportional hazard model was used for univariate and multivariate analyses to identify independent prognostic factors. The optimal cut‑off values for Cys C, UA and LDH were 0.775 mg/l, 296.45 µmol/l and 198.5 U/l, respectively. The survival curves demonstrated that progression‑free survival (PFS) and overall survival (OS) time were shorter in patients with high levels of Cys C, UA and LDH prior to chemotherapy. Univariate and multivariate analyses indicated that LDH concentration prior to chemotherapy may be an independent prognostic factor for both PFS and OS in patients with SCLC, while Cys C concentration may be an independent prognostic factor for PFS in patients with SCLC. The concentrations of Cys C, UA and LDH prior to chemotherapy were associated with prognosis of patients with SCLC. PFS and OS time were shorter, and the prognosis was poor in patients with elevated serum levels of Cys C, UA and LDH. Taken together, the results of the present study suggest that high concentrations of LDH and Cys C prior to chemotherapy may indicate rapid disease progression, thus it is important to focus on the progression and recurrence of the disease. High LDH concentration may also indicate a shorter survival time.

View Figures

View References

1	van Meerbeeck JP, Fennell DA and De Ruysscher DK: Small-Cell lung cancer. Lancet. 378:1741–1755. 2011. View Article : Google Scholar : PubMed/NCBI
2	Amini A, Byers LA, Welsh JW and Komaki RU: Progress in the management of limited-stage small cell lung cancer. Cancer. 120:790–798. 2014. View Article : Google Scholar : PubMed/NCBI
3	Kiani A, Khosravi A, Moghaddam AS, Jabbari H and Fakhri M: Long-Term survival of a small cell lung cancer patient with proper endobronchial management. Pneumologia. 61:245–248. 2012.PubMed/NCBI
4	Poola I and Graziano SL: Expression of neuron-specific enolase, chromogranin A, synaptophysin and Leu-7 in lung cancer cell lines. J Exp Clin Cancer Res. 17:165–173. 1998.PubMed/NCBI
5	Yang X, Wang D, Yang Z, Qing Y, Zhang Z, Wang G, Yang Z and Wang Z: CEA is an independent prognostic indicator that is associated with reduced survival and liver metastases in SCLC. Cell Biochem Biophys. 59:113–119. 2011. View Article : Google Scholar : PubMed/NCBI
6	Molina R, Auge JM, Escudero JM, Marrades R, Viñolas N, Carcereny E, Ramirez J and Filella X: Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as tumor markers in patients with lung cancer: Comparison with CYFRA 21-1, CEA, SCC and NSE. Tumour Biol. 29:371–380. 2008. View Article : Google Scholar : PubMed/NCBI
7	Winther B, Moi P, Paus E and Reubsaet JL: Targeted determination of the early stage SCLC specific biomarker pro-gastrin-releasing peptide (ProGRP) at clinical concentration levels in human serum using LC-MS. J Sep Sci. 30:2638–2646. 2007. View Article : Google Scholar : PubMed/NCBI
8	Nakai K, Kikuchi M, Fujimoto K, Kaneko Y, Omori S, Nakai K and Suwabe A: Serum levels of cystatin C in patients with malignancy. Clin Exp Nephrol. 12:132–139. 2008. View Article : Google Scholar : PubMed/NCBI
9	Kos J, Krasovec M, Cimerman N, Nielsen HJ, Christensen IJ and Brünner N: Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: Relation to prognosis. Clin Cancer Res. 6:505–511. 2000.PubMed/NCBI
10	Ames BN, Cathcart R, Schwiers E and Hochstein P: Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: A hypothesis. Proc Natl Acad Sci USA. 78:6858–6862. 1981. View Article : Google Scholar : PubMed/NCBI
11	Vona-Davis L, Howard-McNatt M and Rose DP: Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev. 8:395–408. 2007. View Article : Google Scholar : PubMed/NCBI
12	Dang CV and Lewis BC: Role of oncogenic transcription factor c-myc in cell cycle regulation, apoptosis and metabolism. J Biomed Sci. 4:269–278. 1997. View Article : Google Scholar : PubMed/NCBI
13	Naumnik W, Niklińska W, Ossolińska M and Chyczewska E: Serum cathepsin K and cystatin C concentration in patients with advanced non-small-cell lung cancer during chemotherapy. Folia Histochem Cytobiol. 47:207–213. 2009. View Article : Google Scholar : PubMed/NCBI
14	Parks SK, Chiche J and Pouysségur J: Disrupting proton dynamics and energy metabolism for cancer therapy. Nat Rev Cancer. 13:611–623. 2013. View Article : Google Scholar : PubMed/NCBI
15	Micke P, Faldum A, Metz T, Beeh KM, Bittinger F, Hengstler JG and Buhl R: Staging small cell lung cancer: Veterans administration lung study group versus international association for the study of lung cancer-what limits limited disease? Lung Cancer. 37:271–276. 2002. View Article : Google Scholar : PubMed/NCBI
16	Ghaemi-Oskouie F and Shi Y: The role of uric acid as an endogenous danger signal in immunity and inflammation. Curr Rheumatol Rep. 13:160–166. 2011. View Article : Google Scholar : PubMed/NCBI
17	Fantin VR, St-Pierre J and Leder P: Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. 9:425–434. 2006. View Article : Google Scholar : PubMed/NCBI
18	Lewis BC, Shim H, Li Q, Wu CS, Lee LA, Maity A and Dang CV: Identification of putative c-myc-responsive genes: Characterization of rcl, a novel growth-related gene. Mol Cell Biol. 17:4967–4978. 1997. View Article : Google Scholar : PubMed/NCBI
19	Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA, Dalla-Favera R and Dang CV: C-Myc transactivation of LDH-A: Implications for tumor metabolism and growth. Proc Natl Acad Sci USA. 94:6658–6663. 1997. View Article : Google Scholar : PubMed/NCBI
20	Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Trarbach T, Folprecht G, Shi MM, Lebwohl D, Jalava T, Laurent D, et al: Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy. Clin Cancer Res. 17:4892–4900. 2011. View Article : Google Scholar : PubMed/NCBI
21	Turen S, Ozyar E, Altundag K, Gullu I and Atahan IL: Serum lactate dehydrogenase level is a prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy. Cancer Invest. 25:315–321. 2007. View Article : Google Scholar : PubMed/NCBI
22	Jin Y, Ye X, Shao L, Lin BC, He CX, Zhang BB and Zhang YP: Serum lactic dehydrogenase strongly predicts survival in metastatic nasopharyngeal carcinoma treated with palliative chemotherapy. Eur J Cancer. 49:1619–1626. 2013. View Article : Google Scholar : PubMed/NCBI
23	Brown JE, Cook RJ, Lipton A and Coleman RE: Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: A retrospective analysis in bisphosphonate-treated patients. Clin Cancer Res. 18:6348–6355. 2012. View Article : Google Scholar : PubMed/NCBI
24	Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA and Vogelzang NJ: Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 21:1232–1237. 2003. View Article : Google Scholar : PubMed/NCBI
25	von Eyben FE, Madsen EL, Liu F, Amato R and Fritsche H: Serum lactate dehydrogenase isoenzyme 1 as a prognostic predictor for metastatic testicular germ cell tumours. Br J Cancer. 83:1256–1259. 2000. View Article : Google Scholar : PubMed/NCBI
26	Gerlinger M, Wilson P, Powles T and Shamash J: Elevated LDH predicts poor outcome of recurrent germ cell tumours treated with dose dense chemotherapy. Eur J Cancer. 46:2913–2918. 2010. View Article : Google Scholar : PubMed/NCBI
27	Egberts F, Kotthoff EM, Gerdes S, Egberts JH, Weichenthal M and Hauschild A: Comparative study of YKL-40, S-100B and LDH as monitoring tools for stage IV melanoma. Eur J Cancer. 48:695–702. 2012. View Article : Google Scholar : PubMed/NCBI
28	Agarwala SS, Keilholz U, Gilles E, Bedikian AY, Wu J, Kay R, Stein CA, Itri LM, Suciu S and Eggermont AM: LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur J Cancer. 45:1807–1814. 2009. View Article : Google Scholar : PubMed/NCBI
29	Seagroves TN, Ryan HE, Lu H, Wouters BG, Knapp M, Thibault P, Laderoute K and Johnson RS: Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells. Mol Cell Biol. 21:3436–3444. 2001. View Article : Google Scholar : PubMed/NCBI
30	Schofield CJ and Ratcliffe PJ: Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol. 5:343–354. 2004. View Article : Google Scholar : PubMed/NCBI
31	Ostergaard L, Tietze A, Nielsen T, Drasbek KR, Mouridsen K, Jespersen SN and Horsman MR: The relationship between tumor blood flow, angiogenesis, tumor hypoxia, and aerobic glycolysis. Cancer Res. 73:5618–5624. 2013. View Article : Google Scholar : PubMed/NCBI
32	Ryberg M, Nielsen D, Osterlind K, Skovsgaard T and Dombernowsky P: Prognostic factors and long-term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapy. Ann Oncol. 12:81–87. 2001. View Article : Google Scholar : PubMed/NCBI
33	Brizel DM, Schroeder T, Scher RL, Walenta S, Clough RW, Dewhirst MW and Mueller-Klieser W: Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Physics. 51:349–353. 2001. View Article : Google Scholar
34	Ervin H and Cox JL: Late stage inhibition of hematogenous melanoma metastasis by cystatin C over-expression. Cancer Cell Int. 5:142005. View Article : Google Scholar : PubMed/NCBI
35	Sevier CS and Kaiser CA: Formation and transfer of disulphide bonds in living cells. Nat Rev Mol Cell Biol. 3:836–847. 2002. View Article : Google Scholar : PubMed/NCBI
36	Choi SW and Mason JB: Folate and carcinogenesis: An integrated scheme. J Nutr. 130:129–132. 2000. View Article : Google Scholar : PubMed/NCBI
37	Saleh Y, Sebzda T, Warwas M, Kopec W, Ziólkowska J and Siewinski M: Expression of cystatin C in clinical human colorectal cancer tissues. J Exp Ther Oncol. 5:49–53. 2005.PubMed/NCBI
38	Zhang X, Hou Y, Niu Z, Li W, Meng X, Zhang N and Yang S: Clinical significance of detection of cathepsin X and cystatin C in the sera of patients with lung cancer. Zhongguo Fei Ai Za Zhi. 16:411–416. 2013.(In Chinese). PubMed/NCBI
39	Hammarsten J, Damber JE, Peeker R, Mellström D and Högstedt B: A higher prediagnostic insulin level is a prospective risk factor for incident prostate cancer. Cancer Epidemiol. 34:574–579. 2010. View Article : Google Scholar : PubMed/NCBI
40	Bjorge T, Lukanova A, Jonsson H, Tretli S, Ulmer H, Manjer J, Stocks T, Selmer R, Nagel G, Almquist M, et al: Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project. Cancer Epidemiol Biomarkers Prev. 19:1737–1745. 2010. View Article : Google Scholar : PubMed/NCBI
41	Rose DP, Haffner SM and Baillargeon J: Adiposity, the metabolic syndrome, and breast cancer in African-American and white American women. Endocr Rev. 28:763–777. 2007. View Article : Google Scholar : PubMed/NCBI
42	Giovannucci E: Metabolic syndrome, hyperinsulinemia, and colon cancer: A review. Am J Clin Nutr. 86:s836–s842. 2007. View Article : Google Scholar : PubMed/NCBI
43	Siddiqui AA: Metabolic syndrome and its association with colorectal cancer: A review. Am J Med Sci. 341:227–231. 2011. View Article : Google Scholar : PubMed/NCBI
44	Linder N, Butzow R, Lassus H, Lundin M and Lundin J: Decreased xanthine oxidoreductase (XOR) is associated with a worse prognosis in patients with serous ovarian carcinoma. Gynecol Oncol. 124:311–318. 2012. View Article : Google Scholar : PubMed/NCBI
45	Herrmann MK, Bloch E, Overbeck T, Koerber W, Wolff HA, Hille A, Vorwerk H, Hess CF, Muller M, Christiansen H and Pradier O: Mediastinal radiotherapy after multidrug chemotherapy and prophylactic cranial irradiation in patients with SCLC-treatment results after long-term follow-up and literature overview. Cancer Radiother. 15:81–88. 2011. View Article : Google Scholar : PubMed/NCBI
46	Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G and Piedbois P; Mata-analysis Group in Cancer, : Re: A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer. J Natl Cancer Inst. 93:399–401. 2001. View Article : Google Scholar : PubMed/NCBI
47	Abdelwahab S, Abdulla H, Azmy A, Abdelfatah A, Abdel-Aziz H, Margerges M, Riad A, Sharma V and Dwedar I: Integration of irinotecan and cisplatin with early concurrent conventional radiotherapy for limited-disease SCLC (LD-SCLC). Int J Clin Oncol. 14:230–236. 2009. View Article : Google Scholar : PubMed/NCBI